Free tool
FAERS Monitor: Tepmetko
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214096 or its brand name (Tepmetko, Tepotinib Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
691
Serious
489
71% of reports
Hospitalization
188
Death reported
163
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death114
- oedema66
- diarrhoea58
- oedema peripheral58
- fatigue56
- renal impairment56
- off label use55
- nausea44
- disease progression43
- peripheral swelling39
- decreased appetite27
- blood creatinine increased24
- dyspnoea20
- constipation19
- pleural effusion19
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 4 |
| 2021 | 69 |
| 2022 | 81 |
| 2023 | 183 |
| 2024 | 92 |
| 2025 | 105 |
| 2026 | 157 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,468 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| oedemaSignal | 66 | 37.1 | 29.5 | 2,285 |
| renal impairmentSignal | 56 | 20.3 | 15.8 | 1,012 |
| oedema peripheralSignal | 58 | 14.5 | 11.3 | 719 |
| blood creatinine increasedSignal | 24 | 11.2 | 7.6 | 213 |
| disease progressionSignal | 43 | 11.1 | 8.3 | 386 |
| pleural effusionSignal | 19 | 9.5 | 6.1 | 137 |
| peripheral swellingSignal | 39 | 7.7 | 5.7 | 223 |
| deathSignal | 114 | 4.0 | 3.4 | 267 |
| decreased appetiteSignal | 27 | 3.5 | 2.4 | 47 |
| diarrhoeaSignal | 58 | 2.7 | 2.1 | 64 |
| constipationSignal | 19 | 2.7 | 1.7 | 18 |
| fatigueSignal | 56 | 2.2 | 1.7 | 36 |
| off label use | 55 | 1.9 | 1.5 | 24 |
| nausea | 44 | 1.7 | 1.3 | 12 |
| dyspnoea | 20 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.